At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,930 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating Placebo, Dasatinib, and 2 other interventions for Prostatic Neoplasms. Completed, enrolled 1,930 participants across 186 sites in 25 countries.
Detailed Summary
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms
CountriesArgentina, Australia, Brazil, Canada, Czechia, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russia, South Africa, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionAug 2012
Study CompletionJul 2015
TodayJul 2026
First PostedSep 1, 2008
Enrollment StartOct 1, 2008
Primary CompletionAug 1, 2012
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.8 years ago
Interventions
Placebodrug
Dasatinibdrug
Docetaxeldrug
Prednisonedrug